Does Semaglutide Burn Fat, and How Does It Actually Work?

How does semaglutide burn fat if it never touches a fat cell?

This is a question our prescribers hear most weeks, and the short answer is: semaglutide does not act on fat cells at all. What it does is mimic a naturally occurring gut hormone called GLP-1 (glucagon-like peptide-1), which signals fullness to the brain and slows gastric emptying. The practical result is that hunger arrives later, portions feel satisfying sooner, and cravings (particularly for high-calorie foods) tend to quieten.

Fat loss follows from what happens next. When calorie intake falls consistently below the amount your body needs to maintain its current weight, it begins converting stored fat into energy. Semaglutide creates the conditions for that deficit; the fat loss is a downstream consequence, not a direct pharmacological effect on adipose tissue. You can read a clear account of this mechanism on the NHS semaglutide medicines page. For a closer look at how this plays out in practice, the semaglutide function page goes into further detail.

One thing worth knowing: because gastric emptying slows, the deficit builds gradually rather than through a dramatic overnight drop in appetite. Most people notice the shift in hunger over the first few weeks of treatment, and it tends to deepen as the dose is titrated upward by the prescriber.

Does Wegovy specifically burn belly fat, or does fat loss happen all over?

Wegovy is the UK brand name for semaglutide used for weight management, and if you are wondering whether Wegovy helps burn fat in a targeted way or across the body as a whole, the answer is that fat loss is systemic rather than directed at one area. The body decides where it draws from based on individual physiology, genetics, sex hormones and starting composition, not the medicine itself. There is no mechanism by which a GLP-1 medicine can instruct the body to prioritise the abdomen, thighs, or any other region.

That said, clinical studies do show meaningful reductions in waist circumference alongside overall body weight, which suggests visceral fat (the metabolically active fat stored around internal organs) is reduced as part of the overall loss. This matters clinically because visceral fat is associated with cardiovascular risk and metabolic dysfunction. For the detailed evidence on abdominal changes specifically, the semaglutide and belly fat page covers what the trial data shows.

The short version: semaglutide supports fat loss throughout the body. Where you lose it first or most is something your biology decides, not your prescription.

Does semaglutide burn fat or muscle, and does it matter?

Any significant calorie deficit carries some risk of lean mass loss alongside fat, and semaglutide is not an exception to that principle. In the STEP 1 trial, the majority of weight lost was body fat, but a portion was lean mass. The proportions vary depending on factors including protein intake, physical activity levels and how quickly the dose is increased.

This is one reason the licensed guidance positions semaglutide alongside a reduced-calorie diet and increased physical activity, not as a standalone fix. Adequate protein and resistance exercise are commonly recommended by clinicians to help preserve muscle during weight loss on GLP-1 medicines, though the specifics of any dietary or exercise plan should come from your prescriber or a dietitian, not from a webpage. There is a fuller treatment of this topic on the fat versus muscle page.

If you are considering treatment and want to understand what it would mean for your own body composition, that is exactly the kind of thing to raise during your clinical assessment. At nume, consultations are reviewed personally by a GPhC-registered Independent Prescriber, who can address your individual picture rather than giving a generic answer.

Who is eligible for semaglutide, and what does the evidence say about results?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber weighs your full medical history, current medicines and circumstances before recommending any treatment; BMI alone does not determine suitability.

The trial evidence is published and peer-reviewed. STEP 1 (68 weeks, 2.4mg semaglutide versus placebo, adults with obesity or overweight plus a weight-related condition, no diabetes) showed an average body-weight reduction of around 15%. A higher maintenance dose of 7.2mg is now also MHRA-approved in a dedicated single-dose pen, with trial data showing average reductions approaching 20.7% at that dose. The semaglutide fat loss page covers the full results picture, including what trial participants' experiences looked like week to week.

For a broader overview of the medicine itself, the Wegovy treatment page brings together licensing, dosing and access information. If you are weighing up whether to explore treatment, the free consultation page is the place to start, your details are reviewed the same day by a real clinician, and there is no obligation to proceed.